Tong-Ming Fu

Tong-Ming Fu

UNVERIFIED PROFILE

Are you Tong-Ming Fu?   Register this Author

Register author
Tong-Ming Fu

Tong-Ming Fu

Publications by authors named "Tong-Ming Fu"

Are you Tong-Ming Fu?   Register this Author

60Publications

1693Reads

16Profile Views

Neutralizing Monoclonal Antibodies Reduce Human Cytomegalovirus Infection and Spread in Developing Placentas.

Vaccines (Basel) 2019 Sep 29;7(4). Epub 2019 Sep 29.

Department of Cell and Tissue Biology, University of California, San Francisco, CA 94143, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/vaccines7040135DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963214PMC
September 2019

Identification of adipocyte plasma membrane-associated protein as a novel modulator of human cytomegalovirus infection.

PLoS Pathog 2019 07 29;15(7):e1007914. Epub 2019 Jul 29.

Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Texas, United States of America.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.ppat.1007914DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6687193PMC
July 2019

Human cytomegalovirus vaccine development: Immune responses to look into vaccine strategy.

Hum Vaccin Immunother 2018 02 1;14(2):292-303. Epub 2017 Dec 1.

a State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, School of Life Science , Xiamen University , Xiamen , Fujian , China.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/21645515.2017.1
Publisher Site
http://dx.doi.org/10.1080/21645515.2017.1391433DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806647PMC
February 2018

Targeting Human-Cytomegalovirus-Infected Cells by Redirecting T Cells Using an Anti-CD3/Anti-Glycoprotein B Bispecific Antibody.

Antimicrob Agents Chemother 2018 01 21;62(1). Epub 2017 Dec 21.

Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/AAC.01719-17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5740302PMC
January 2018

Antibody therapies for the prevention and treatment of viral infections.

NPJ Vaccines 2017 10;2:19. Epub 2017 Jul 10.

Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41541-017-0019-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627241PMC
July 2017

Establishment and validation of an enzyme-linked immunosorbent assay for IgG antibody against cytomegalovirus based on pp150 antigen.

J Virol Methods 2017 02 4;240:21-25. Epub 2016 Nov 4.

State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Science and School of Public Health, Xiamen University, Xiamen 361005, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jviromet.2016.11.001DOI Listing
February 2017

Genome Sequences of Diverse Human Cytomegalovirus Strains with Utility in Drug Screening and Vaccine Evaluation.

Genome Announc 2017 Jan 19;5(3). Epub 2017 Jan 19.

Department of Microbiology and Immunology, Lineberger Comprehensive Cancer Center Program in Global Oncology, Center for AIDS Research (CfAR), School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/genomeA.01433-16DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5255926PMC
January 2017

Preclinical evaluations of peptide-conjugate vaccines targeting the antigenic domain-2 of glycoprotein B of human cytomegalovirus.

Hum Vaccin Immunother 2016 08 17;12(8):2106-2112. Epub 2016 Mar 17.

a Merck Research Laboratories, Merck and Companies, Incorporated , Kenilworth , NJ , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/21645515.2016.1164376DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994730PMC
August 2016

Functional analysis of human cytomegalovirus UL/b' region using SCID-hu mouse model.

J Med Virol 2016 08 4;88(8):1417-26. Epub 2016 Feb 4.

Department of Microbiology and Molecular Genetics, Rutgers-New Jersey Medical School, Newark, New Jersey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jmv.24484DOI Listing
August 2016

Progress on human cytomegalovirus vaccines for prevention of congenital infection and disease.

Curr Opin Virol 2014 Jun 14;6:13-23. Epub 2014 Mar 14.

Department of Vaccines Research, Merck Research Laboratories, West Point, PA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.coviro.2014.02.004DOI Listing
June 2014

Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease.

Vaccine 2014 May 28;32(22):2525-33. Epub 2014 Mar 28.

Merck Research Laboratories, Merck and Co., Inc., West Point, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2014.03.057DOI Listing
May 2014

Evidence for cyclic diguanylate as a vaccine adjuvant with novel immunostimulatory activities.

Cell Immunol 2012 Jul-Aug;278(1-2):113-9. Epub 2012 Aug 4.

Merck Sharp & Dohme Corp., Whitehouse Station, NJ, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cellimm.2012.07.006DOI Listing
January 2013

Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection.

Vaccine 2011 Nov 22;29(48):9075-80. Epub 2011 Sep 22.

Department of Vaccine Research, Merck Research Laboratories, WP16-200, 770 Sumneytown Pike, West Point, PA 19486, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2011.09.056DOI Listing
November 2011

Evaluating functional antibodies in rhesus monkeys immunized with hepatitis B virus surface antigen vaccine with novel adjuvant formulations.

Vaccine 2011 Nov 11;29(50):9385-90. Epub 2011 Oct 11.

Department of Vaccine Basic Research, Department of Vaccine Processing Research and Development, Merck Research Laboratories, West Point, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2011.09.122DOI Listing
November 2011

A novel high-throughput neutralization assay for supporting clinical evaluations of human cytomegalovirus vaccines.

Vaccine 2011 Oct 31;29(46):8350-6. Epub 2011 Aug 31.

Vaccines Research, Merck Research Laboratories, West Point, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2011.08.086DOI Listing
October 2011

Development and evaluation of an M2-293FT cell-based flow cytometric assay for quantification of antibody response to native form of matrix protein 2 of influenza A viruses.

J Immunol Methods 2011 Jun 1;369(1-2):115-24. Epub 2011 May 1.

Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jim.2011.04.010DOI Listing
June 2011

Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys.

Vaccine 2009 Feb 13;27(9):1440-7. Epub 2009 Jan 13.

Department of Vaccine Basic Research, Merck Research Laboratories, West Point, PA 19486, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2008.12.034DOI Listing
February 2009

Maturation of recombinant hepatitis B virus surface antigen particles.

Hum Vaccin 2006 Jul-Aug;2(4):174-80. Epub 2006 Jul 9.

Department of Bioprocess & Bioanalytical Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.2.4.3015DOI Listing
October 2006

High-potency human immunodeficiency virus vaccination leads to delayed and reduced CD8+ T-cell expansion but improved virus control.

J Virol 2005 Aug;79(15):10059-62

Department of Haematology, Prince of Wales Hospital and Centre for Vascular Research, University of New South Wales, Kensington, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/JVI.79.15.10059-10062.2005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1181589PMC
August 2005

Development of HIV-1 Nef vaccine components: immunogenicity study of Nef mutants lacking myristoylation and dileucine motif in mice.

Vaccine 2002 Sep;20(27-28):3413-21

Merck Research Laboratories, Department of Virus & Cell Biology, Merck and Co. Inc., Sumneytown Pike, P.O. Box 4, West Point, PA 19486, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0264-410x(02)00308-0DOI Listing
September 2002